Researchers conducted a metaumbrella review of 34 systematic reviews and 70 studies, uncovering a significant link between ...

leaving 1,820 patients with COPD for inclusion in the study. The study flowchart is presented in Figure 1. The diagnosis of COPD was established based on one or more of the following criteria (21): (1 ...

The flowchart of participant inclusion and exclusion is depicted ... Subgroup analyses of NLR and mortality risk in COPD. These results indicate that the relationship between higher NLR and increased ...

Dupixent approved in China as the first-ever biologic medicine for patients with chronic obstructive pulmonary disease (COPD). September 27, 2024. Accessed September 27, 2024.

Over the last decade, as other companies—such as AstraZeneca with IL-5 inhibitor Fasenra—struggled to advance candidates for COPD, Regeneron and Sanofi took a more “phenotype-driven approach ...

Introduction Fluoroquinolones can cause severe collagen-associated adverse effects, potentially impacting the pulmonary ...

Dupixent is already a blockbuster therapy for a range of immune-mediated diseases, but the Food and Drug Administration’s approval of the drug for chronic obstructive pulmonary disease greatly ...

Teamwork: A Multidisciplinary Approach to Early Lung Cancer: Personalized Care A nurse practitioner with NYU's pulmonary intervention team chronicles the NSCLC patient experience from diagnosis to ...

The certificate noted that the stroke was caused by cerebral vascular disease, which affects blood flow in the brain, and that Fritz also suffered from COPD and aortic stenosis, which affects ...

The characteristics of the men in the two groups are shown in Table 1, and a detailed flow chart showing the numbers of men who discontinued and continued participation throughout the trial is ...